Status:
UNKNOWN
Gut Microbiota Association With ESBL-E Colonisation and Subsequent ESBL-E Infection
Lead Sponsor:
University of Bordeaux
Conditions:
Extended Spectrum Beta-Lactamase Producing Bacteria Infection
Microbial Colonization
Eligibility:
All Genders
18+ years
Brief Summary
Antimicrobial resistance is a major threat worldwide and extended-spectrum beta-lactamase producing Enterobacteriales (ESBL-E) are a leading cause because of their wide dissemination. Gut microbiota s...
Detailed Description
The rising antimicrobial resistance has led to more than 33,000 deaths in Europe in 2015. Among them, extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) are the most frequent in Eu...
Eligibility Criteria
Inclusion
- Patient above 18 year-old admitted to intensive care unit
- ESBL-E fecal carriage according to current screening recommendations for ESBL-E carriage group
- Feces quantity on rectal swab adequate for routine screening and microbiota analysis
Exclusion
- Guardianship, curatorship, or prisoners
- No health insurance
- No legal representative
Key Trial Info
Start Date :
October 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 15 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04131569
Start Date
October 15 2019
End Date
March 15 2020
Last Update
October 21 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical intensive care unit, Pelelgrin hospital
Bordeaux, Nouvelle-Aquitaine, France, 33000